Clinical trial NCT00003270
Conditions: Graft Versus Host Disease Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes
Keywords: recurrent childhood acute lymphoblastic leukemia recurrent adult Hodgkin lymphoma Burkitt lymphoma refractory multiple myeloma stage I multiple myeloma stage II multiple myeloma stage III multiple myeloma recurrent childhood lymphoblastic lymphoma recurrent childhood acute myeloid leukemia recurrent adult acute myeloid leukemia recurrent adult acute lymphoblastic leukemia relapsing chronic myelogenous leukemia childhood diffuse large cell lymphoma childhood immunoblastic large cell lymphoma chronic phase chronic myelogenous leukemia accelerated phase chronic myelogenous leukemia blastic phase chronic myelogenous leukemia meningeal chronic myelogenous leukemia adult acute myeloid leukemia in remission adult acute lymphoblastic leukemia in remission childhood acute myeloid leukemia in remission childhood acute lymphoblastic leukemia in remission recurrent/refractory childhood Hodgkin lymphoma recurrent grade 1 follicular lymphoma recurrent grade 2 follicular lymphoma recurrent grade 3 follicular lymphoma recurrent adult diffuse small cleaved cell lymphoma recurrent adult diffuse mixed cell lymphoma recurrent adult diffuse large cell lymphoma recurrent adult immunoblastic large cell lymphoma recurrent adult lymphoblastic lymphoma recurrent adult Burkitt lymphoma secondary acute myeloid leukemia de novo myelodysplastic syndromes previously treated myelodysplastic syndromes secondary myelodysplastic syndromes graft versus host disease recurrent childhood small noncleaved cell lymphoma recurrent childhood large cell lymphoma recurrent mantle cell lymphoma recurrent marginal zone lymphoma recurrent small lymphocytic lymphoma extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue nodal marginal zone B-cell lymphoma splenic marginal zone lymphoma childhood myelodysplastic syndromes
Sponsor: Roswell Park Cancer Institute
Start date: 1997-09-04; Completion date: 2017-10-16
Enrollment: 20 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Umbilical cord blood transplantation may allow doctors to give higher doses of chemotherapy or radiation therapy and kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of chemotherapy, radiation therapy, and umbilical cord blood transplantation in treating patients with hematologic cancer.

Detailed description:
OBJECTIVES: I. Determine the safety, efficacy, and toxicity of using cord blood as a source for stem cell transplantation in patients with hematologic malignancies.

OUTLINE: Patients undergo autologous bone marrow harvesting or peripheral stem cell collection prior to transplant regimen, unless the patient has acute leukemia in relapse, aplastic anemia, or myelodysplastic syndrome. Arm I: Patients eligible to undergo total body irradiation (TBI) first receive cyclophosphamide IV over 2 hours on days -5 and -4, then undergo TBI twice a day on days -3 to -1. Patients also receive antithymocyte globulin (ATG) IV over 10 hours on days -3 to -1. Cord blood is infused on day 0. Arm II: Patients not eligible to receive TBI receive oral busulfan every 6 hours on days -7 to -4 for a total of 16 doses. Cyclophosphamide, ATG, and cord blood are then administered as in arm I. All patients receive cyclosporine on days -2 to 180, methylprednisolone on days 5-180, and filgrastim (G-CSF) from day 1. Patients are followed weekly until day 180 and then monthly for 2 years.

PROJECTED ACCRUAL: A total of 20 patients (10 patients per arm) will be accrued for this study within 4 years.

Arms: arm 1: Patients eligible to undergo total body irradiation (TBI) first receive cyclophosphamide IV over 2 hours on days -5 and -4, then undergo TBI twice a day on days -3 to -1. Patients also receive antithymocyte globulin (ATG) IV over 10 hours on days -3 to -1. Cord blood is infused on day 0
Interventions: intervention 1: anti-thymocyte globulin intervention 2: filgrastim intervention 3: busulfan intervention 4: cyclophosphamide intervention 5: cyclosporine intervention 6: methylprednisolone intervention 7: bone marrow ablation with stem cell support intervention 8: umbilical cord blood transplantation intervention 9: radiation therapy
Intervention descriptions: intervention 1: IV intervention 2: IV intervention 3: IV intervention 4: IV intervention 5: IV intervention 6: IV intervention 7: IV intervention 8: IV intervention 9: High energy X-rays

Protocol documents:
Prot_SAP_000.pdf: 
APPROVED RPCI IRB
7/7/2017


APPROV
O ED
E  RPCI IRB
7/7/2017


APPR
P OVED RPCI IRB
7/7/2017


APPROVED RPCI IRB
7/7/2017


APPROV
O ED RPCI IRB
7/7/2017


APPROVED RPCI IRB
7/7/2017


APPROVED RPCI IR
I B
7/7/2017


APPROVED RPC
P I IRB
7/7/2017


APPROV
O ED
E  RPCI IRB
7/7/2017


APPROVED
ED
ED RPCI IRB
7/7/2017


APPROV
O ED
ED
ED
ED RPCI IRB
7/7/2017


AP
A PROVED RPCI IRB
7/7/2017


APPROV
OV
OV
OVED RPCI IRB
7/7/2017


AP
A PROVED RPCI IRB
7/7/2017


APPROVED RPCI IRB
7/7/2017


AP
A PROVED RPCI IR
I B
7/7/2017


APPROV
OV
OV
OVED RPCI IRB
7/7/2017


APPR
P OVED RPC
PC
PCI IRB
7/7/2017


APPROV
O ED RPCI IRB
7/7/2017